pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

7,948 catalysts · 5,063 phase readout · 2,317 8k filing · 316 pdufa · 273 earnings · 108 phase 2 completion · 50 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 21 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout5,063
  • 8k filing2,317
  • pdufa316
  • earnings273
  • phase 2 completion108
  • phase 1 completion50
  • phase 1 2 completion28
  • phase 1 initiation22
  • phase 0 trial completion21
  • phase 1 2 initiation9
  • therapy area
    • Oncology87
    • Cardiology23
    • Immunology15
    • Infectious Disease12
    • Dermatology12
    • Ophthalmology8
    • Women's Health8
    • Pulmonology8
    • Pain6

    Date TBD

    50
    ›RECRUITINGphase readoutNCT07173166: Non-Pharmacological Interventions for Neurotoxicity in Hematologic Patients Receiving CAR-T Therapy

    Sponsor: Instituto de Investigacion Sanitaria INCLIVA. Phase: NA. Conditions: Hematologic Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT00024622: PET Scanning in Parkinson s Disease

    Sponsor: National Institute of Mental Health (NIMH). Phase: . Conditions: Schizophrenia, Parkinson's Disease

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07486102: A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems

    Sponsor: Boehringer Ingelheim. Phase: PHASE1. Conditions: Healthy, Hepatic Impairment

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06853002: Deep Breathing Exercises and Incentive Spirometry After Rib Fracture

    Sponsor: Samsun University. Phase: NA. Conditions: Rib Fractures, Oxygenation

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07495137: The Improvement Effect of Real-time Artificial Intelligence Assisted Identification of Bleeding Points on Hemostasis Efficiency in Endoscopic Submucosal Dissection

    Sponsor: Qilu Hospital of Shandong University. Phase: NA. Conditions: Endoscopic Submucosal Dissection, Endoscopic Submucosal Dissection (ESD)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07145437: Prostate Stereotactic Radiation and Radio-induced Lymphocyte Apoptosis for Predicting Late Toxicities in Prostate Cancer (PROSTERA)

    Sponsor: Clinique Sainte Clotilde. Phase: NA. Conditions: Prostate Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05729945: Catholic Health Initiatives (CHI) St. Joseph's Children Home Visiting Longitudinal Study

    Sponsor: University of New Mexico. Phase: NA. Conditions: Child Development, Child Behavior, Child Abuse, Child Neglect, Parenting, Delinquency, Criminal Behavior

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05746039: Feasibility of Semaglutide in Advanced Lung Disease

    Sponsor: University of Pennsylvania. Phase: PHASE1. Conditions: Obesity, Interstitial Lung Disease, Chronic Obstructive Pulmonary Disease, Sarcoidosis, Pulmonary, Pulmonary Hypertension

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05756777: A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: PHASE1. Conditions: Acute Myeloid Leukemia (AML)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06282601: STUDY OF THE EFFECT OF RHYTHMIC AND NON-RHYTHMIC MUSICAL PRIMING ON THE SYNTAX CAPACITY OF PRESBYACOUSTIC OLDER ADULTS

    Sponsor: Centre Hospitalier Universitaire Dijon. Phase: NA. Conditions: Presbyacousie

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07114601: A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Sponsor: Eli Lilly and Company. Phase: PHASE1. Conditions: Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms, Neoplasm Metastasis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05929001: Lymphedema Specific PROs for Risk Assessment, Prevention and Early Detection

    Sponsor: University of Miami. Phase: . Conditions: Lymphedema

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03136601: Percutaneous Tibial Nerve Stimulation Maintenance: Monthly Therapy or Per Patient Requested Need

    Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center. Phase: NA. Conditions: Overactive Bladder

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

    Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto. Phase: PHASE2. Conditions: Chemotherapy, Leukemia, Acute Lymphoblastic

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07203001: A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

    Sponsor: Novartis Pharmaceuticals. Phase: PHASE2. Conditions: Still´s Disease

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06410001: CE-STAND: Cervical Epidural STimulation After Neurologic Damage

    Sponsor: University of Minnesota. Phase: PHASE1. Conditions: Spinal Cord Injury

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07535801: Recording Stress Biomarkers in Autism Spectrum Disorders

    Sponsor: Universite Cote d'Azur. Phase: . Conditions: Autism Spectrum Disorder With Intellectual Deficiency

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

    Sponsor: National Cancer Institute (NCI). Phase: PHASE1. Conditions: Metastatic Colorectal Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03947619: Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

    Sponsor: Abiomed Inc.. Phase: NA. Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07336030: Effect of Baduanjin Exercise in Diabetic Patients

    Sponsor: Cairo University. Phase: NA. Conditions: Diabetes Mellitus

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06623630: Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function

    Sponsor: Washington University School of Medicine. Phase: PHASE1. Conditions: Multiple Myeloma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT01375530: Screening Volunteers for Clinical Trials

    Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Phase: . Conditions: Screening

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07457528: Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

    Sponsor: Tianjin Medical University Cancer Institute and Hospital. Phase: PHASE2. Conditions: Resectable Esophageal Squamous Cell Carcinoma

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07550465: Study of QLS1410 in the Treatment of Primary Aldosteronism.

    Sponsor: Qilu Pharmaceutical Co., Ltd.. Phase: PHASE2. Conditions: Primary Aldosteronism

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT06682767: A Nutritional Intervention for Body, Brain, and Longevity Effects (NIBBLE)

    Sponsor: Cedars-Sinai Medical Center. Phase: NA. Conditions: Cerebral Blood Flow, APOE 4

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03835767: Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

    Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Phase: PHASE2. Conditions: Milk and/or Peanut Allergy

    full page →ctgov ↗
    ›ENROLLING_BY_INVITATIONphase readoutNCT07380867: Confirming the Accuracy of Endoscopic Marking Using a New Marker, a Novel Luminomarker, in Lesion Marking Before Colorectal Cancer Surgery.

    Sponsor: Seoul St. Mary's Hospital. Phase: NA. Conditions: Colorectal Cancer, Endoscopic Tattoo of Suspected Colon Cancer, Indocyanine Green (ICG)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05852600: Parent-focused Intervention to Reduce HIV Risk in Gay and Bisexual Adolescents

    Sponsor: George Washington University. Phase: NA. Conditions: Hiv, Sexual Health

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05843565: Standard Versus Hyperangulated Video Laryngoscopy Blades for Intubation in Neonates and Small Infants

    Sponsor: American University of Beirut Medical Center. Phase: NA. Conditions: Intubation; Difficult or Failed

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06575400: A Study to Test How Well Different Doses of BI 3804379 Are Tolerated by Healthy People

    Sponsor: Boehringer Ingelheim. Phase: PHASE1. Conditions: Healthy

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04526600: Fidgeting and Attentional and Emotional Regulation in ADHD

    Sponsor: University of California, Davis. Phase: NA. Conditions: ADHD

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05467800: Study of Canakinumab in Patients With Myelofibrosis

    Sponsor: John Mascarenhas. Phase: PHASE2. Conditions: Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05168605: Assessing the Efficacy of Targeted Home Visits in the Management of Chronic Conditions

    Sponsor: University of Texas Southwestern Medical Center. Phase: NA. Conditions: Hypertension, Type 2 Diabetes

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07181005: The Validity and Reliability of an Improved Paper Grasping Test for Stroke

    Sponsor: Sanko University. Phase: . Conditions: Stroke, Balance, Validity and Safety

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07469241: Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caicinoma.

    Sponsor: Fudan University. Phase: PHASE2. Conditions: Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07168200: A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

    Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd. Phase: PHASE3. Conditions: Advanced Cervical Cancer

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03301792: Group Versus Traditional Prenatal Care for Diabetes

    Sponsor: Washington University School of Medicine. Phase: NA. Conditions: Pregnancy, Gestational Diabetes, Type 2 Diabetes

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07422792: Anabolic Response To Intravenous Amino Acids In Chronic Intestinal Failure Patients

    Sponsor: Institute of Oncology Ljubljana. Phase: NA. Conditions: Chronic Intestinal Failure, Intestinal Failure, Home Parenteral Nutrition

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06582771: A Study of Sotorasib in People With Non-Small Cell Lung Cancer

    Sponsor: Memorial Sloan Kettering Cancer Center. Phase: PHASE2. Conditions: Non Small Lung Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06961071: Parathyroid Allotransplant for Treatment of Hypoparathyroidism

    Sponsor: Peter Stock. Phase: PHASE1. Conditions: Hypoparathyroidism, Hypoparathyroidism Postprocedural, Hypoparathyroidism Post-surgical

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07318844: Stroke Volume at Rest and During Exercise in Healthy Volunteers

    Sponsor: Rigshospitalet, Denmark. Phase: NA. Conditions: Healthy

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07476664: Acute Oroantral Communication Closure: Resorbable Collagen Membrane vs. Buccal Advancement Flap Outcomes

    Sponsor: Medical University of Silesia. Phase: NA. Conditions: Oroantral Communication, Acute Oroantral Communication, Oroantral Fistula, Post-extraction Maxillary Sinus Communication

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07452809: Results Between Robotic-assisted and Manual Total Knee Arthroplasty With Kinematic Alignment

    Sponsor: Jakub Błaszczyk. Phase: NA. Conditions: Knee Arthritis, Osteoarthritis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04868032: Gaining Optimism After Weight Loss Surgery (GOALS) II

    Sponsor: Massachusetts General Hospital. Phase: NA. Conditions: Bariatric Surgery

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07508098: Comparison of Efficacy of Topical Westerhoff Formula Cream Vs Topical 4% Hydroquinone for the Treatment of Melasma

    Sponsor: Pak Emirates Military Hospital. Phase: PHASE4. Conditions: Melasma (Facial Melasma)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05361798: A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

    Sponsor: National Cancer Institute (NCI). Phase: PHASE2. Conditions: Cancer Of Prostate

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT03065387: Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

    Sponsor: M.D. Anderson Cancer Center. Phase: PHASE1. Conditions: Advanced Malignant Solid Neoplasm, EGFR Gene Amplification, EGFR Gene Mutation, ERBB2 Gene Amplification, ERBB2 Gene Mutation, ERBB3 Gene Mutation, ERBB4 Gene Mutation, KRAS Gene Mutation, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06555393: Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study

    Sponsor: University of Alberta. Phase: PHASE1. Conditions: High Blood Sugar, High Blood Pressure, Overweight and Obesity

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07440706: Continuous Glucose Monitoring With iCan i3 in Post-Bariatric Patients With Late Dumping Syndrome

    Sponsor: Kaiser Clinic and Hospital. Phase: NA. Conditions: Dumping Syndrome, Post-bariatric Hypoglycemia

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT07523204: Photobiomodulation Therapy for Scar Quality After Facial Wound Closure

    Sponsor: Hani M. Al-Kufi. Phase: NA. Conditions: Traumatic Facial Wounds

    full page →ctgov ↗
    ← prev
    page 62 of 159
    next →